Flow cytometric analysis of cellular changes in mice after intradermal inoculation with a liposome-iscom adjuvanted vaccine

Scandinavian Journal of Immunology

Volumn 47, Issue 3, 1998, Pages 243-253

  San Gil, F ^a,b   Turner, B ^a   Mullbacher, A ^c   Walker, M J ^b   Djordjevic, S P ^a   Eamens, G J ^a   Chin, J C ^a,d  

^a NSW AGRICULTURE   (Australia)

^b UNIVERSITY OF WOLLONGONG   (Australia)

^c Biology and Environment   (Australia)

^d NSW DEPARTMENT OF PRIMARY INDUSTRIES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLIPOSOME; ISCOM; OUTER MEMBRANE PROTEIN; OVALBUMIN; SAMA 4 ANTIGEN; UNCLASSIFIED DRUG;

ACTINOBACILLUS PLEUROPNEUMONIAE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; FEMALE; FLOW CYTOMETRY; GRANULOCYTE; HISTOPATHOLOGY; INTRADERMAL DRUG ADMINISTRATION; LEUKOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; VACCINATION;

EID: 0031976252     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1998.00304.x     Document Type: Article

References (76)

1. Landsteiner K, Jacobs J. Studies on the sensitization of animals with simple chemical compounds. J Exp Med 1935;61:643-56.
2. Dresser DW. Effectiveness of lipid and lipophilic substances as adjuvants. Nature 1961;191:1169-71.
3. Staruch MJ, Wood DD. The adjuvanticity of interleukin I in vivo. J Immunol 1983;130:2191-4.
4. Cooper PD. Vaccine adjuvants based on gamma-inulin. In: Borchardt RT, ed. Vaccine Design: The Subunit and Adjuvant Approach. Vol. 6, 1st edn. New York: Plenum Press, 1995:559-76.
5. Beh KJ, Lascelles AK. The effect of adjuvants and prior immunization on the rate and mode of uptake of antigen into afferent popliteal lymph from sheep. Immunol 1985;54:487-95.
6. Hunter R, Strickland F, Kezdy F. The adjuvant activity of nonionic block polymer surfactants. J Immunol 1981;127:1244-50.
7. Lascelles AK, Eagleson G, Beh KJ, Watson DL. Significance of Freund's adjuvant/antigen injection granuloma in the maintenance of serum antibody response. Vet Immunol Immunopathol 1989;22:15-27.
8. Morein B, Fossum C, Lovgren K, Hoglund S. The iscom - a modern approach to vaccines. Sem Virol 1990;1:49-55.
9. Herbert WJ. The mode of action of mineral-oil emulsion adjuvants on antibody production in mice. Immunol 1968;14:301-18.
10. Frost P, Lance EM. On the mechanism of action of adjuvants. Immunol 1978;36:63-8.
11. Bokhout BA, van der Heijden PJ, Nabuurs MJA, Pals JW, Scholten JW, Stok W. Adjuvant application without antigen for prevention of diseases in piglets. Effects obtained by manipulation of the immune system. In: Cancellotti FM, Galassi D, eds. Agriculture: Adjuvants, Interferon and Non-Specific Immunity. Brussels: Commission of the European Communities, 1984:101-7.
12. Reynolds JA, Harrington DG, Crabbs CL, Peters CJ, DiLuzio NR. Adjuvant activity of a novel metabolizable lipid emulsion with inactivated viral vaccines. Infect Immun 1980;28:937-43.
13. Hilgers LAT, Snippe H, Jansze M, Willers JMN. Immunomodulating properties of two synthetic adjuvants: dependence upon type of antigen, dose, and time of administration. Cell Immunol 1984;86:393-401.
14. Nervig RM, Gough PM, Kaeberle ML, Whetstone CA. Advances in Carriers and Adjuvants for Veterinary Biologies, 1st edn. Iowa: Iowa State University Press, 1986:14.
15. Thapar M, Parr E, Bozzola J, Parr M. Secretory immune responses in the mouse vagina after parenteral or intravaginal immunization with an immunostimulating complex (ISCOM). Vaccine 1991;9:129-33.
16. Phillips NC, Emili A. Enhanced antibody response to liposome-associated protein antigens: preferential stimulation of IgG2a/b production. Vaccine 1992;10:151-8.
17. de Haan A, Geerligs HJ, Huchshorn JP, van Scharrenhurg GJM, Palache AM, Wilschut J. Mucosal immunoadjuvant activity of liposomes: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes. Vaccine 1995;13:155-62.
18. Barr IG, Mitchell GF. ISCOMs (immunostimulating complexes): the first decade. Immunol Cell Biol 1996;74:8-25.
19. Chin JC, Eamans G, Turner B. Manipulating mucosal immune responses by intradermal immunization. J Cell Biochem 1993;17:54.
20. Chin J-C. Composition for use in increasing mucosal immunity. Provisional Patent Specification. 1994.
21. Chin JC, San Gil F, Novak M et al. Manipulating systemic and mucosal immune responses with skin-deliverable adjuvants. J Biotechnol 1996;44:13-9.
22. Chin JC, Dai Y. Selective extraction of outer membrane proteins from membrane complexes of Pseudomonas maltophila by chloroform-methanol. Vet Microbiol 1990;22:69-78.
23. Chin JC, Turner B. Extraction of membrane antigens from Brucella ovis and an assessment of their serological activity by immunoblotting. J Gen Microbiol 1990;136:1615-22.
24. Schmid I, Uittenbogaart CH, Keld B, Giorgi JV. A rapid method for measuring apoptosis and dual-colour immunofluorescence by single laser flow cytometry. J Immunol Meth 1994;170:145-57.
25. Holt P, Degebrodt A, Venaille T et al. Preparation of interstitial lung cells by enzymatic digestion of tissue slices: preliminary characterization by morphology and performance in functional assays. Immunol 1985;54:139-47.
26. Douglas RS, Tarshis AD, Pletcher CH, Nowell PC, Moore JS. A simplified method for the coordinate examination of apoptosis and surface phenotype of murine lymphocytes. J Immunol Meth 1995;188:219-28.
27. Freund J. The mode of action of immunologic adjuvants. Advances in Tuberculosis Research 1956;7:130-47.
28. Vogel FR, Powell MF. Compendium of vaccine adjuvants and excipients. In: Borchardt RT, ed. Vaccine Design: The Subunit and Adjuvant Approach, Vol. 6, 1st edn. New York: Plenum Press, 1995:142-211.
29. Snippe H, Beider M, Willers JMN. Dimethyl dioctadecyl ammonium bromide as adjuvant for delayed hypersensitivity in mice. Immunol 1977;33:931-6.
30. Flebbe L, Braley-Mullen H. Immunopotentiating effects of the adjuvants SGP and Quil A. Cell Immunol 1986;99:119-27.
31. Lycke N, Holmgren J. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunol 1986;59:301-8.
32. Bennett B, Check IJ, Olsen MR, Hunter RL. A comparison of commercially available adjuvants for use in research. J Immunol Meth 1992;153:31-40.
33. Daynes RA, Araneo BA. The development of effective vaccine adjuvants employing natural regulators of T-cell lymphokine production in vivo. Proc Natl Acad Sci USA 1994;730:144-61.
34. Dong P, Brunn C, Ho RJY. Cytokines as vaccine adjuvants. In: Borchardt RT, ed. Vaccine Design: The Subunit and Adjuvant Approach, Vol. 6, 1st edn. New York: Plenum Press, 1995:625-39.
35. Lachman LB, Shin L-CN, Rao X-M, Ullrich SE, Cleland JL. Cytokine-containing liposomes as adjuvants for subunit vaccines. In: Borchardt RT, ed. Vaccine Design: The Subunit and Adjuvant Approach, Vol. 6, 1st edn. New York: Plenum Press, 1995:659-71.
36. Djordjevic SP, Eamans GJ, Romalis LF, Nicholls PJ, Taylor V, Chin J. Serum and mucosal antibody responses and protection in pigs vaccinated against Mycoplasma hyopnuemoniae with vaccines containing denatured membrane antigen pool and adjuvant. Aust Vet J 1997;5:504-11.
37. Morein B, Sundquist B, Hoglund S, Dalsgaard K, Osterhaus A. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 1984;308:457-60.
38. Watson D, Lovgren K, Watson N, Fossum C, Morein B, Hoglund S. Inflammatory responses and antigen localization following immunization with influenza virus ISCOMs. Inflammation 1989;13:641-9.
39. Sundquist B, Lovgren K, Morein B. Influenza virus ISCOMs: antibody response in animals. Vaccine 1988;6:49-53.
40. Fossum C, Bergstrom M, Lovgren K, Watson DL, Morein B. Effects of iscoms and their adjuvant moiety (matrix) on the initial proliferation and IL-2 responses: comparison of spleen cells from mice inoculated with iscoms and/or matrix. Cell Immunol 1990;129:414-25.
41. Speijers G, Danse L, Beuvery E, Strik J, Vos J. Local reactions of the saponin Quil A and a Quil A containing iscom measles vaccine after intramuscular injection of rats: a comparison with the effect of DPT-polio vaccine. Fund Appl Toxicol 1988;10:425-30.
42. Maudsley JR, Kadis S, Mayberry WR. Isolation, purification, and partial characterization of a lipopolysaccharide from Haemophilus pleuropneumoniae. Infect Immun 1986;51:501-6.
43. Yokochi T, Inoue Y, Yokoo J, Kimura Y, Kato N. Retention of bacterial lipopolysaccharide at the site of subcutaneous injection. Infect Immun 1989;57:1786-91.
44. Yokochi T, Inoue Y, Miyadai T, Kimura Y, Ito H, Kato N. A possible correlation between histological changes in regional subcutaneous tissue induced by bacterial lipopolysaccharides and their adjuvant activities. Microbiol Immunol 1989;33:747-60.
45. Thomas DJ, Caffrey TC. Lipopolysaccharide induced double-stranded DNA fragmentation in mouse thymus: protective effect of zinc pretreatment. Toxicol 1991;68:327-37.
46. Chang YF, Young RY, Struck DK. Cloning and characterization of a haemolysin gene from Actinobacillus (Haemophilus) pleuropneumoniae. DNA 1989;8:635-47.
47. Jianneng M, Inzana T, Rapid purification of a 110 kd haemolysin of Actinobacillus pleuropneumoniae by monoclonal antibody-affinity chromatography. Am J Vet Res 1990;53:59-62.
48. Frey J, Bosse J, Chang J-T et al. Actinobacillus pleuropneumoniae RTX-toxins: uniform designation of haemolysins, cytolysins, pleurotoxins and their genes. J Gen Microhiol 1993;139:1723-8.
49. Morein B, Sharp M, Sundquist B, Simons K. Protein subunit vaccines of parainfluenza type 3 virus: immunogenic effect in lambs and mice. J Gen Virol 1983;64:1557-69.
50. Ozel M, Hoglund S, Gelderblom H, Morein B. Quaternary structure of the immunostimulating complex (Iscom). J Ultrastruct Mol Struct Res 1989;102:240-8.
51. Watson DL, Watson NA, Fossum C, Lovgren K, Morein B. Interactions between immune-stimulating complexes (ISCOMs) and peritoneal mononuclear leucocytes. Microbiol Immunol 1992;36:199-203.
52. Sibille Y, Reynolds HY. Macrophages and polymorphonuclear neutrophils in lung defense and injury. Am Rev Resp Dis 1990;141:471-501.
53. Harmsen A, Muggenburg B, Burton Snipes M, Bice D. The role of macrophages in particle translocation from lungs to lymph nodes. Science 1985;230:1277-80.
54. Bellingan GJ, Caldwell H, Howie SEM, Drainsfield I, Haslett C. In vivo fate of the inflammatory macrophage during the resolution of inflammation. J Immunol 1996;157:2577-85.
55. Hardy J. Haematology of rats and mice. In: Cotchin E, Coe FJ, eds. Pathology of Laboratory Rats and Mice. Oxford: Blackwell Scientific Publications, 1967:520-4.
56. Loeb WF, Bannerman RM, Rininger BF, Johnson AJ. The evaluation of the hemic system. In: Benirschke K, Garner FM, Jones TC, eds. Pathology of Laboratory Animals, Vol. 1. New York: Springer-Verlag, 1978:918-9.
57. Colditz IG, Kerlin RL, Watson DL. Migration of neutrophils and their role in elaboration of host defense. In: Husband AJ, ed. Migration and Homing of Lymphoid Cells, Vol. 1. Boca Raton: CRC Press, 1988:135-65.
58. Godfraind C, Holmes KV, Coutelier J-P. Thymus involution induced by mouse hepatitis virus A59 in BALB/c mice. J Virol 1995;69:6541-7.
59. Vaux DL, Strasser A. The molecular biology of apoptosis. Proc Natl Acad Sci USA 1996;93:2239-44.
60. Pruett SB, Barnes DB, Han YC, Munson AE. Immunotoxicological characteristics of sodium methyldithiocarbamate. Fund Appl Toxicol 1992;18:40-7.
61. Han YC, Lin TL, Pruett SB. Thymic atrophy caused by ethanol in a mouse model for binge drinking: involvement of endogenous glucocorticoids. Toxicol Appl Pharmacol 1993;123:16-25.
62. Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 1980;284:555-6.
63. Duvall E, Wyllie AH, Morris RG. Macrophage recognition of cells undergoing programmed cell death (apoptosis). Immunol 1985;56:351-8.
64. Savill J, Fadok V, Henson P, Haslett C. Phagocyte recognition of cells undergoing apoptosis. Immunol Today 1993;14:131-6.
65. Surh CD, Sprent J. T-cell apoptosis detected in situ during positive and negative selection in the thymus. Nature 1994;372:100-3.
66. Bryant BJ, Hess MW, Cottier H. Efflux and restoration phases after peripheral exposure of mice to phytohaemagglutinin. Immunol 1975;29:115-20.
67. Rothenb EV. Death and transfiguration of cortical thymocytes: a reconsideration. Immunol Today 1990;11:116-9.
68. Vacchio MS, Papadopoulos V, Ashwell JD. Steroid production in the thymus: implications for thymocyte selection. J Exp Med 1994;179:1835-46.
69. Nieuwenhuis P, Stet RJM, Kampinga J, Karrenbeld A. The transcapsular route: A new way for (self-)antigens to by-pass the blood-thymus barrier? Immunol Today 1988;9:372-5.
70. + thymocytes in suspension culture by extrathymic antigen-presenting cells. Nature 1991;351:150-3.
71. Westermann J, Smith T, Peters U et al. Both activated and non-activated leukocytes from the periphery continuously enter the thymic medulla of adult rats: phenotypes, sources and magnitude of traffic. Eur J Immunol 1996;26:1866-74.
72. + cytotoxic T lymphocytes towards soluble antigens: immunostimulating-ovalbumin complexes enter the class I MHC-restricted antigen pathway and allow sensitization against the immunodominant peptide. Eur J Immunol 1991;21:1523-7.
73. Maloy KJ, Donachie AM, O'Hagan DT, Mowat AM. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly (lactide-co-glycolide) microparticles. Immunol 1994;81:661-7.
74. - lymphocytes (putative γδ T cells). Immunol 1991;74:234-9.
75. Mowat AM, Donachie A, Reid G, Jarrett O. Immune-stimulating complexes containing Quil A and protein antigen prime class I MHC-restricted T lymphocytes in vivo and are immunogenic by the oral route. Immunol 1991;72:317-22.
76. Lehninger AL. Biochemistry, 2nd edn. New York: Worth Publishers Inc. 1975.